These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 17653494

  • 1. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?
    Vellas B, Andrieu S, Cantet C, Dartigues JF, Gauthier S.
    J Nutr Health Aging; 2007; 11(4):338-41. PubMed ID: 17653494
    [Abstract] [Full Text] [Related]

  • 2. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.
    Helmer C, Andrieu S, Pérès K, Orgogozo JM, Vellas B, Dartigues JF, REAL.fr Group.
    Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578
    [Abstract] [Full Text] [Related]

  • 3. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
    Rockwood K, Dai D, Mitnitski A.
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
    [Abstract] [Full Text] [Related]

  • 4. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F, Portet F, Touchon J, Vellas B.
    J Nutr Health Aging; 2007 Feb; 11(4):330-7. PubMed ID: 17653493
    [Abstract] [Full Text] [Related]

  • 5. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW, Yik PY, Mok W, Chung CP.
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [Abstract] [Full Text] [Related]

  • 6. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
    Rockwood K, Fay S, Gorman M.
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
    [Abstract] [Full Text] [Related]

  • 7. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
    Hanon O, Latour F, Seux ML, Lenoir H, Forette F, Rigaud AS, REAL.FR Group.
    J Nutr Health Aging; 2005 Feb; 9(2):106-11. PubMed ID: 15791354
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
    Wattmo C, Hansson O, Wallin AK, Londos E, Minthon L.
    Dement Geriatr Cogn Disord; 2008 Feb; 26(3):203-11. PubMed ID: 18769065
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R, Ferris S, Robert P, Winblad B, Gauthier S, Tennigkeit F.
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [Abstract] [Full Text] [Related]

  • 12. Long-term progression of Alzheimer's disease in patients under antidementia drugs.
    Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, Gauthier S, Ousset PJ, Vellas B, REAL.FR study group.
    Alzheimers Dement; 2011 Nov; 7(6):579-92. PubMed ID: 22055975
    [Abstract] [Full Text] [Related]

  • 13. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I.
    Dement Geriatr Cogn Disord; 2007 Nov; 23(5):301-6. PubMed ID: 17356273
    [Abstract] [Full Text] [Related]

  • 14. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC, Shiovitz TM, Tariot PN, Porsteinsson AP, Baker KD, Feldman PD.
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [Abstract] [Full Text] [Related]

  • 15. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N, Ott BR, Peskind E, Resnick EM.
    Alzheimer Dis Assoc Disord; 2007 Sep; 21(1):60-4. PubMed ID: 17334274
    [Abstract] [Full Text] [Related]

  • 16. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
    Wiig EH, Annas P, Basun H, Andreasen N, Lannfelt L, Zetterberg H, Blennow K, Minthon L.
    Acta Neurol Scand; 2010 Mar; 121(3):186-93. PubMed ID: 19785641
    [Abstract] [Full Text] [Related]

  • 17. Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR Study.
    Cortes F, Nourhashémi F, Guérin O, Cantet C, Gillette-Guyonnet S, Andrieu S, Ousset PJ, Vellas B, REAL-FR Group.
    Alzheimers Dement; 2008 Jan; 4(1):22-9. PubMed ID: 18631947
    [Abstract] [Full Text] [Related]

  • 18. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
    Borkowska A, Ziolkowska-Kochan M, Rybakowski JK.
    Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
    [Abstract] [Full Text] [Related]

  • 19. A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in an Icelandic elderly population.
    Hannesdóttir K, Snaedal J.
    Nord J Psychiatry; 2002 Aug; 56(3):201-6. PubMed ID: 12079572
    [Abstract] [Full Text] [Related]

  • 20. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D, Andersen HF.
    Dement Geriatr Cogn Disord; 2007 Aug; 24(2):138-45. PubMed ID: 17622761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.